Partial
Partially Aligned
Patient Risk:
Info
Summary
Some statements about ADDYI’s labeled indication and key safety/interaction concepts are consistent with the provided label text. However, multiple statements about “generic availability,” approval status, who manufactures generics, and expectations about generic bioequivalence are not supported by the provided prescribing information and include unsupported/extra-label assertions.
Category Scores
Accurate Statements
Addyi is approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).
Supported: Indications and Usage state ADDYI is indicated for women less than 65 years of age with acquired, generalized HSDD (not due to co-existing medical/psychiatric condition, relationship problems, or effects of medications/other drug substances). Provided label context corresponds to premenopausal population via the “less than 65 years of age” description.
A 'generic Addyi' would mean a flibanserin product approved as bioequivalent to the branded drug.
Partially supported by label framing of “bioequivalent” as the concept of generic substitution is not explicitly stated in the provided sections; however, no direct contradiction to the provided label text. Marked accurate only in the sense that this statement does not conflict with any supplied label content.
Differences can still show up in inactive ingredients even if a generic is bioequivalent.
No explicit statement in provided label text. Not contradicted by supplied label excerpts.
If/when a generic is approved, it is expected to match Addyi’s active ingredient (flibanserin).
Not explicitly stated in provided label text; no direct contradiction in supplied excerpts.
If/when a generic is approved, it is expected to be bioequivalent to Addyi.
Not explicitly stated in provided label text; no direct contradiction in supplied excerpts.
There is not enough detail provided to confirm whether a generic flibanserin (Addyi) is currently on the market.
Supported: The provided prescribing information sections do not address current market status of generics.
There is not enough detail provided to confirm who would make a generic flibanserin (Addyi).
Supported: Provided prescribing information does not identify manufacturers of potential generic versions.
There is not enough detail provided to confirm whether an FDA approval for generic flibanserin (Addyi) has occurred.
Supported: Provided prescribing information does not state any generic approval status.
Unsupported Statements
Addyi is the brand name for flibanserin.
The provided label excerpts do not explicitly state that ADDYI’s generic name is flibanserin.
If a generic exists, it would be made by an FDA-approved manufacturer of flibanserin.
The provided label does not discuss generic manufacturing requirements or what entity would make a generic.
If a generic exists, it would list flibanserin as the active ingredient.
The provided label does not discuss how generics are labeled or the active ingredient listing for generics.
Generic availability depends on patent expiry.
The provided label does not address patents or how patent expiry affects generic availability.
Generic availability depends on remaining regulatory exclusivity.
The provided label does not address regulatory exclusivity or its role in generic availability.
Regulatory exclusivity can delay approval or launch even after a patent-related event.
The provided label does not address regulatory exclusivity timelines or interactions with patents.
The goal of generic approval is to achieve the same exposure and dosing behavior.
The provided label does not discuss goals or criteria of generic approval in terms of exposure/dosing behavior.
For flibanserin, a main patient-facing concern is safety guidance that can depend on prescriber instructions.
The provided label includes patient counseling information, but it does not characterize “main” concerns as dependent on prescriber instructions.
Safety guidance for flibanserin can depend on instructions around alcohol and drug interactions.
The label supports specific counseling about alcohol and certain drug interactions; however, the statement as phrased about “can depend on instructions around” is an extra characterization not explicitly stated in the provided text.
Contradictions
Low
AI Statement
Even with generics, patients should follow the same clinician directions they had with Addyi.
Label Reference
No direct contradiction found, but this is not explicitly supported in the provided label excerpts (the label provides instructions for ADDYI specifically, not generic products).
Important Omissions
The AI response did not make (or evaluate) any label-supported dosing instructions such as bedtime-only administration, missed dose handling, or counseling to avoid alcohol until the following day and to avoid full alertness activities for at least 6 hours.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The generics/market-existence assertions are largely unsupported by the provided label and could mislead, but they do not directly assert incorrect contraindications or incorrect dosing. Safety-related statements are partially aligned with labeled counseling (alcohol/CYP3A4 interactions), though some are phrased broadly beyond what the label states.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims about generic existence, manufacturing, patent/exclusivity effects, and generic approval goals are not supported by the provided prescribing information.
Suggested Improvement
Restrict claims to what the provided label text supports (e.g., ADDYI’s indication, contraindications, and specific patient counseling about alcohol and CYP3A4 inhibitors). Avoid statements about generic availability/approvals/manufacturers/patents/exclusivity unless the supplied label includes that information.